(a) Clinical efficacy of tocilizumab (Tocilizumab combination therapy)
| Study | Population | Week at evaluation | Treatment arms | Patient number | HAQ (% ≥MCID) | Response rates (%), OR (95% CI) | DAS28 < 2.6 remission rate (%), OR (95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| ACR20 | ACR50 | ACR70 | |||||||
| TOWARD | DMARDs-IR | 24 W | TCZ (8 mg/kg) + DMARDs | 803 | 60**** | 61**** | 38**** | 21**** | 30****, 13.8 |
| DMARDs | 413 | 34 | 25 | 9 | 3 | 3 | |||
|
| |||||||||
| RADIATE | Anti-TNF-IR | 24 W | TCZ (4 mg/kg) + MTX | 161 | Δ − 0.3** | 30*** | 17**** | 5 | 8, 4.3 |
| TCZ (8 mg/kg) + MTX | 170 | Δ − 0.4**** | 50*** | 29**** | 12**** | 30***, 21 | |||
| MTX | 158 | Δ − 0.1 | 10 | 4 | 1 | 2 | |||
|
| |||||||||
| OPTION | MTX-IR | 24 W | TCZ (4 mg/kg) + MTX | 214 | Δ − 0.52* | 48****, 2.6 (1.7–3.9) | 31****, 3.8 (2.3–6.5) | 12****, 7.0 (2.4–20.4) | 13***, 18.8 (2.5–142) |
| TCZ (8 mg/kg) + MTX | 205 | Δ − 0.55** | 59****, 4.0 (2.6–6.1) | 44****, 6.6 (3.9–11.2) | 22****, 14.2 (5.0–40.4) | 27****, 45 (6.1–332) | |||
| MTX | 204 | Δ − 0.34 | 26 | 11 | 2 | 1 | |||
|
| |||||||||
| LITHE | MTX-IR | 52 W | TCZ (4 mg/kg) + MTX | 399 | 60 | 47* | 29* | 16* | 30*, 4.92 |
| TCZ (8 mg/kg) + MTX | 398 | 63* | 56**** | 36**** | 20**** | 47****, 10.2 | |||
| MTX | 393 | 53 | 25 | 10 | 4 | 8 | |||